誉衡药业
(002437)
| 流通市值：68.13亿 | | | 总市值：72.99亿 |
| 流通股本：20.96亿 | | | 总股本：22.46亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,099,501,266.79 | 551,255,672.12 | 2,440,732,030.17 | 1,857,506,712.57 |
| 营业收入 | 1,099,501,266.79 | 551,255,672.12 | 2,440,732,030.17 | 1,857,506,712.57 |
| 二、营业总成本 | 977,868,310.54 | 493,551,043.76 | 2,218,794,751.25 | 1,686,482,833.11 |
| 营业成本 | 579,512,077.52 | 281,637,041.68 | 1,135,911,990.4 | 868,397,419.79 |
| 税金及附加 | 16,446,942.36 | 8,690,670.16 | 33,805,563.23 | 25,272,388.83 |
| 销售费用 | 294,238,047.8 | 158,753,641.89 | 792,647,941.82 | 631,722,798.46 |
| 管理费用 | 56,753,730.91 | 29,190,700.92 | 166,704,878.22 | 110,018,674.56 |
| 研发费用 | 30,316,235.75 | 15,046,259.26 | 90,792,091.72 | 48,755,362.8 |
| 财务费用 | 601,276.2 | 232,729.85 | -1,067,714.14 | 2,316,188.67 |
| 其中:利息费用 | 2,340,656.38 | 136,814.28 | 9,820,044.88 | 8,734,869.94 |
| 其中:利息收入 | 2,546,567.2 | 1,415,676.57 | 9,959,815.69 | 7,888,828.78 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 8,559,844.12 | 3,559,330.01 | -13,979,364.47 | -5,108,803.07 |
| 加:投资收益 | 175,170.34 | 186,760.17 | 5,250,989.35 | 5,987,857.43 |
| 资产处置收益 | 3,660,243.29 | 3,400,000 | 3,395,603.19 | 1,587,450.4 |
| 资产减值损失(新) | -906,206.2 | -263,230.63 | -4,866,432.46 | -585,236.29 |
| 信用减值损失(新) | -4,538.7 | 76,048.59 | 1,417,486.85 | 1,208,038.24 |
| 其他收益 | 18,755,923.47 | 4,406,097.57 | 71,697,423.25 | 48,187,810.86 |
| 四、营业利润 | 151,873,392.57 | 69,069,634.07 | 284,852,984.63 | 222,300,997.03 |
| 加:营业外收入 | 458,669.14 | 44,415.91 | 1,215,971.16 | 103,541 |
| 减:营业外支出 | 243,050.22 | 163,826.36 | 2,376,835.33 | 346,651.03 |
| 五、利润总额 | 152,089,011.49 | 68,950,223.62 | 283,692,120.46 | 222,057,887 |
| 减:所得税费用 | 14,664,998.51 | 7,018,639 | 41,152,085.53 | 30,271,571.05 |
| 六、净利润 | 137,424,012.98 | 61,931,584.62 | 242,540,034.93 | 191,786,315.95 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 137,424,012.98 | 61,931,584.62 | 242,540,034.93 | 191,786,315.95 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 134,422,001.01 | 60,252,267.26 | 232,759,457.12 | 183,485,762.41 |
| 少数股东损益 | 3,002,011.97 | 1,679,317.36 | 9,780,577.81 | 8,300,553.54 |
| 扣除非经常损益后的净利润 | 106,654,653.85 | 49,733,030.46 | 183,308,910.66 | 142,885,487.4 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.03 | 0.11 | 0.08 |
| (二)稀释每股收益 | 0.06 | 0.03 | 0.1 | 0.08 |
| 八、其他综合收益 | -159,250.63 | -40,526.17 | 476,998.7 | -388,301 |
| 归属于母公司股东的其他综合收益 | -159,250.63 | -40,526.17 | 476,998.7 | -388,301 |
| 九、综合收益总额 | 137,264,762.35 | 61,891,058.45 | 243,017,033.63 | 191,398,014.95 |
| 归属于母公司股东的综合收益总额 | 134,262,750.38 | 60,211,741.09 | 233,236,455.82 | 183,097,461.41 |
| 归属于少数股东的综合收益总额 | 3,002,011.97 | 1,679,317.36 | 9,780,577.81 | 8,300,553.54 |
| 公告日期 | 2025-08-27 | 2025-04-26 | 2025-04-26 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |